Intravitreal tissue plasminogen activator for acute central retinal vein occlusion

Ophthalmic Surgery and Lasers

Volumn 30, Issue 6, 1999, Pages 427-434

  Lahey, J Michael ^a   Fong, Donald S ^b   Kearney, John ^a  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; EYE INFECTION; FEMALE; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MALE; NEOVASCULAR GLAUCOMA; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA HEMORRHAGE; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ACUTE DISEASE; ADULT; AGED; FEMALE; FIBRINOLYTIC AGENTS; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PILOT PROJECTS; RETINAL VEIN OCCLUSION; TISSUE PLASMINOGEN ACTIVATOR; VISUAL ACUITY; VITREOUS BODY;

EID: 0033057873     PISSN: 10823069     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98:271-282.
2. Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: the central vein occlusion study group M report. Ophthalmology. 1995;102:1425-1433.
3. Central Vein Occlusion Study Group. A randomized clinical study of early panretinal photocoagulation for ischemic central vein occlusion: the central vein occlusion study group N report. Ophthalmology. 1995;102:1434-1444.
4. Oncel M, Peyman GA, Khoobehi B. Tissue plasminogen in the treatment of experimental vein occlusion. Retina. 1989;9:1-7.
5. Holmes DR, Califf RM, Topol EJ. Lessons we have learned from the GUSTO trial. J Am Coll Cardiol. 1995;25(Suppl):10-17.
6. Lambrou FH, Snyder RW, Williams GA, Lewandowski M. Treatment of experimental intravitreal fibrin with tissue plasminogen activator. Am J Ophthalmol. 1987;104:619-623.
7. Kimura AE, Reddy CV, Folk JC, et al. Removal of subretinal hemorrhage facilitated by preoperative intravitreal tissue plasminogen activator. Retina. 1994;14:83-84.
8. Takeuchi A, Kricrian G, Hao X-Y, Kenney JW, Marmor M. The rate and source of albumin entry into saline filled experimental retinal detachments. Invest Ophthal Vis Sci. 1994;35:3742-3748.
9. Coll GE, Sparrow JR, Marinovic A, Chang S. Effect of intravitreal plasminogen activator on experimental subretinal hemorrhage. Retina. 1995;15:319-326.
10. Loren LJ, Frade G, Torrado MC, Navarro JL. Thrombus age and tissue plasminogen activator mediated thrombolysis in rats. Thromb Res. 1989;56:67-76.
11. Gaffney PJ, Templeman AD, Curtis AD, Campbell PJ. The stability of tissue plasminogen activator (t-PA). Thromb Haemost. 1983;50:650-651.
12. Johnson MW, Olsen KR, Hernandez E, et al. Retinal toxicity of recombinant tissue plasminogen activator in the rabbit. Arch Ophthalmol. 1990;108:259-263.
13. Central Vein Occlusion Study Group. Baseline and early natural history report. Arch Ophthalmol. 1993;111:1087-1095.
14. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM. Prognostic factors for retinal vein occlusion: a prospective study of 175 cases. Ophthalmology. 1996;103:551-560.
15. Quinlan PM, Elman MJ, Bhatt AK, Mardesich P, Enger C. The natural course of central retinal vein occlusion. Am J Ophthalmol. 1990;110:118-123.
16. Kohner EM, Pettit JE, Hamilton AM, et al. Streptokinase in central retinal vein occlusion: a controlled clinical trial. Br Med J. 1976;1:550-553.
17. Hsia J, Hamilton WP, Kleiman N, et al. for Heparin-Aspirin Reperfusion Trial (HART) Investigators. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1990;323:1433-1437.